University of Thessaly (UTH)
Κλινική και βιολογική σημασία της t(12;21)(p13;q22)(+) οξείας λεμφοβλαστικής λευχαιμίας στον ελληνικό πληθυσμό
Abstract
dc:descriptionΤhe t(12;21)(p13;q22) or otherwise ETV6/RUNX1 gene rearrangement, being the most common genetic abnormality in childhood ALL, is combined with controversial prognostic behavior and frequent late relapses, indicating the need for identification of additional prognostic markers. The prognostic significance of the ETV6/RUNX1 fusion, as a sole abnormality or of the accompanying secondary aberrations, have been debated for the last decade. Furthermore, whether secondary aberrations and co-existing sub-clones are responsible for delayed MRD clearance, moderating outcome in patients with ETV6/RUXN1-positive ALL, remains also to be clarified. Τhe aim of the current thesis was to define the epidemiology and prognostic significance of the ΕΤV6/RUNX1 fusion, as well as to study the relation between the ETV6/RUNX1 aberration and the co-existing subclones and/or secondary aberrations with a) presenting clinical and biological features, b) early response to treatment (MRD/MRD log-reduction) and c) long-term outcome in pediatric ALL patients. All 204 patients studied in the current thesis were consecutively diagnosed and homogeneously treated according to BFM-based protocols. 41/204 patients (20,1%) were ETV6/RUNX1-positive. 31/41 ETV6/RUNX1-positive patients (75,6%) harbored additional genetic abnormalities while 18/41 (43,9%) presented with clonal heterogeneity. The most common noticed abnormalities were del12p13(43,9%), 2-3xETV6/RUNX1(19.5%), del9p21(17,1%) and 3-6x21q22(9,8%). The presence of the ΕΤV6/RUNX1 fusion did not have a statistically significant impact on the probability of relapse (RFS 87,8% vs 90,8% in case of translocation absence, p=0,719). Among ETV6/RUNX1(+) pts, children with additional aberrations presented with inferior RFS rates (83,9% vs 100,0% in case of sole abnormality, p=0,03). Additionally, the presence of subclones was associated with dismal prognosis (RFS 72,2% vs 100,0% in pts without subclones, p=0,002). Regarding the accompanying aberrations, the presence of homozygous 9p21 deletion had a statistically significant impact on the probability of relapse (RFS 57,1% vs 94,1% in cases of 9p21 deletion or absence, respectively, p=0,002). MRD-positivity on day 15 of induction was detected in 40,0% of pts with sole ETV6/RUNX1 translocation; the corresponding MRD among ETV6/RUNX1-positive patients carrying subclones rises to 83,3%. Within a median follow-up time of 106 months, 5/41 ETV6/RUNX1(+) patients (12.2%) relapsed; median time of relapse occurrence was 47,8 months compared to 13,3 months among the ETV6/RUNX1(-) subgroup. Common features of all ETV6/RUNX1(+) relapses were sub-clonal diversity and FCM-MRDd15 positivity at a high level(10-3 or 10-2). In conclusion, ETV6/RUNX1+ childhood ALL is characterized by extreme heterogeneity and the prognostic value of the fusion itself varies, depending on coexisting clinical and biological features. The results of the current thesis indicate that the presence of additional genetic aberrations (such as del9p21), clonal heterogeneity and impaired FCM-MRD clearance, influences patient outcome. The presence of clonal heterogeneity and/or clonal evolution is connected to high levels of FC-MRD on day 15 of induction treatment. The fact that, in our series, all late relapses came from the pool of FC-MRDd15 positive patients, strongly supports the hypothesis that the high levels of FC-MRD d15, may serve as a surrogate marker, distinguishing a subgroup of patients with heterogenous outcome; longer follow-up is needed in order to comprehensively study the biology of the disease within this distinct subgroup of ETV6/RUNX1+ patients with delayed clearance. A possible ongoing clonal evolution may further be associated with a greater genetic instability of the ancestral clone. Thus, the results of the current thesis support that clonal heterogeneity may well be driving disparate outcomes, possibly coinciding with other underlying mechanisms. FISH and FCM data may help establish new prognostic markers to predict relapse and refine risk stratification.
Degree
thesis:*- Grantor dc:publisher
- University of Thessaly (UTH)
- Year dc:date
- 2019
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Ampatzidou, Maria
- Αμπατζίδου, Μαρία
Subjects
dc:subject × 14- Οξεία λεμφοβλαστική λευχαιμία της παιδικής ηλικίας
- ETV6/RUNX1 υβριδικό γονίδιο
- Μοριακή γενετική
- t(12;21)(p13;q22) μετάθεση
- Yποκλώνοι και MRD
- Acute lymphoblastic leukaemia of childhood
- ETV6/RUNX1 fusion gene
- Molecular genetics
- t(12;21)(p13;q22) translocation
- Subclones and MRD clearance
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/45267